Nuvation Bio Announces Departure of Chief Financial Officer

(Moderate)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Tags

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

11/13/2023 - 04:05 PM EST

NEW YORK--(BUSINESS WIRE)-- Nuvation Bio Inc. (NYSE: NUVB) (the “Company”) announced today that Jennifer Fox will be stepping down from her role as Chief Financial Officer to pursue a new opportunity. Ms. Fox has advised the Company that she is seeking later stage development and commercial launch experience as part of her career development and that she is leaving with a high regard for the Company, its leadership and its financial state. Ms. Fox submitted her resignation on November 9, 2023 with an effective date of November 27, 2023. Members of the executive management team and the Company’s finance team will assume the duties and responsibilities of the CFO office.

“Jen has played an integral role in helping to set the strategic and financial direction for Nuvation Bio, and I want to thank her for her dedication and hard work in moving Nuvation Bio forward,” said David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio. “We owe her a great deal of gratitude for her contributions and wish her all the best in her future endeavors.”

About Nuvation Bio

Nuvation Bio is a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates. Nuvation Bio’s proprietary portfolio includes mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world’s leading prostate cancer medicines. Nuvation Bio has offices in New York and San Francisco. For more information, please visit www.nuvationbio.com.